Conference abstract
Suggestions for stage I of clinical trials of Diclocor
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Medication Diclocor is the original capsulated pharmaceutical composition which contains classical, non-steroid and antiinflammatory drug diclofenac sodium and a lipoxygenase inhibiting bioflavonoid quercetin. Additionally, it possesses antioxidant, angioprotective, cardioprotective and other activity. The results of the conducted preclinical trials have proven that Diclocor obtains pronounced anti-inflammatory, analgesic, cardioprotective, and chondroprotective activity, which is higher than that of the known drugs like voltaren and quercetin. A prominent feature of this medication is a modifying influence of quercetin on pharmacological and toxicological properties of diclofenac sodium providing for a reduction of the effective dose of diclofenac sodium and, thus, for decrease in side effect incidence and rise of tolerability. It is possible that quercetin enhances bioavailability of diclofenac sodium leading to synergy in the form of potentiating or additive effect. Diclocor is recommended for phase I clinical trials and the suggested schemes are as follows: 1) For single dose tolerability study- 2 capsules (50 mg by diclofenac sodium) and 3 capsules (75 mg by diclofenac sodium); 2) for course dose tolerability study- 1 capsule 2 times a day (50 mg/day by diclofenac sodium) and 2 capsules 2 times a day (100 mg/day by diclofenac sodium). The optimal treatment course length is 7 days.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Oleksii Popov”
- BylineArticles whose byline prints “Sergiy Shebeko”